New 8K just filed
$CNS Pharmaceuticals (CNSP.US)$
Item 8.01Other Events.
As previously disclosed, on September 12, 2024, CNS Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the previous 30 consecutive business days the Company’s common stock had not maintained a closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) because the Company effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one.
The Company requested a hearing before a Hearings Panel (the “Panel”), which hearing will take place on November 5, 2024. The hearing automatically stayed any suspension or delisting action pending the hearing and the expiration of any additional extension period if granted by the Panel following the hearing. There can be no assurance that the Panel will grant the Company an additional extension period beyond the date of hearing.
Item 8.01Other Events.
As previously disclosed, on September 12, 2024, CNS Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the previous 30 consecutive business days the Company’s common stock had not maintained a closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) because the Company effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one.
The Company requested a hearing before a Hearings Panel (the “Panel”), which hearing will take place on November 5, 2024. The hearing automatically stayed any suspension or delisting action pending the hearing and the expiration of any additional extension period if granted by the Panel following the hearing. There can be no assurance that the Panel will grant the Company an additional extension period beyond the date of hearing.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trademark-17 : just tell you this company it's risk fast going up fast it's be down
be cerf
go to $Virax Biolabs (VRAX.US)$ secure company making money
Trytosaveabit OP : In case you don’t read to end! Hehehe ((((. CNS Pharmaceuticals Requested Hearing With Panel on Nov. 5, 2024, Halting Suspension or Delisting Pending Decision )))
F HALE : thank you
Trytosaveabit OP Trademark-17 : Thanks was there about 55 minutes ago when I posted the news! But thanks
Trademark-17 Trytosaveabit OP : when the market it's be open it's go so fast down
unloading 80%
Trademark-17 : between this company and vrax it's big difference- vrax it's have income profits to now 1800%
just started
Trytosaveabit OP Trademark-17 : Yes! But CNSP has a great rare pipeline and it’s sucking so bad because shorts have destroyed it! Hell a few months back it was over 200%SI! Hehehe
Wind_Storm : They need to get this to $1.00+
Trytosaveabit OP Wind_Storm : Yeah but like yesterday! I believe MM’s are going to send huge volume off exchange! Yesterday was 65%+ sent off! Grrr
Trademark-17 : just look vrax very soon 100% up and after boom 2-3 X time up
View more comments...